Human medicines European public assessment report (EPAR): Enzalutamide Accordpharma, enzalutamide, Status: Opinion
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Status: Opinion
Summary of opinion: Minjuvi, 13/11/2025 Positive
Summary of opinion: Veyvondi, 13/11/2025 Positive
Summary of opinion: Koselugo, 13/11/2025 Positive
First gene therapy to treat rare disease Wiskott-Aldrich syndrome
Human medicines European public assessment report (EPAR): Juluca, dolutegravir,rilpivirine, Date of authorisation: 16/05/2018, Revision: 16, Status: Authorised
European Medicines Agency and Transcelerate bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, 17 November 2025
Human medicines European public assessment report (EPAR): Tivicay, dolutegravir, Date of authorisation: 16/01/2014, Revision: 37, Status: Authorised